skip to Main Content

Dr. Tempero on the HALO 301 Trial for Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
OncLive presents videos of cancer researchers discussing their work.
Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the HALO 301 trial, which is exploring the addition of PEGPH20 to gemcitabine and albumin-bound paclitaxel as a potential treatment for patients with pancreatic adenocarcinoma. Watch the video . . .

Back To Top